Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent
Crossref DOI link:
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Reddy, Joseph A.
Santhapuram, Hari Krishna
Vaughn, Jeremy F.
Vlahov, Iontcho R.
Leamon, Christopher P.
Text and Data Mining valid from 2020-07-29
Version of Record valid from 2020-07-29
31 January 2020
9 July 2020
29 July 2020
All authors were employees and stockholders of Endocyte Inc. when these experiments were performed.